Los Angeles Capital Management LLC Sells 50,279 Shares of Insulet Co. (NASDAQ:PODD)

Los Angeles Capital Management LLC reduced its holdings in Insulet Co. (NASDAQ:PODD) by 78.3% during the 3rd quarter, Holdings Channel reports. The fund owned 13,937 shares of the medical instruments supplier’s stock after selling 50,279 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Insulet were worth $3,244,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Sei Investments Co. increased its stake in shares of Insulet by 16.2% in the 1st quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock valued at $2,019,000 after buying an additional 1,639 shares during the period. Inspire Investing LLC grew its stake in Insulet by 26.0% in the first quarter. Inspire Investing LLC now owns 2,581 shares of the medical instruments supplier’s stock valued at $442,000 after acquiring an additional 533 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of Insulet by 3.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 78,435 shares of the medical instruments supplier’s stock worth $13,444,000 after acquiring an additional 2,847 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Insulet by 22.3% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 78,391 shares of the medical instruments supplier’s stock worth $13,436,000 after purchasing an additional 14,289 shares during the period. Finally, Scout Investments Inc. lifted its holdings in shares of Insulet by 178.9% during the 1st quarter. Scout Investments Inc. now owns 144,606 shares of the medical instruments supplier’s stock valued at $24,308,000 after purchasing an additional 92,762 shares in the last quarter.

Insulet Stock Performance

PODD opened at $275.10 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet Co. has a 12-month low of $156.00 and a 12-month high of $279.40. The business has a 50 day moving average of $234.83 and a 200-day moving average of $206.03. The stock has a market cap of $19.29 billion, a price-to-earnings ratio of 47.11, a PEG ratio of 5.00 and a beta of 1.22.

Wall Street Analysts Forecast Growth

PODD has been the topic of several research analyst reports. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. UBS Group upped their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Citigroup boosted their target price on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Canaccord Genuity Group raised their price target on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.